Formycon AG Stock
Price
Target price
€29.15
€29.15
0.520%
0.15
0.520%
€100.00
08:05 / Tradegate
WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Formycon AG is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Formycon
sharewise wants to provide you with the best news and tools for Formycon, so we directly link to the best financial data sources.
Financials
News
Formycon Stock: Biotech Firm Launches First Corporate Bond
Formycon, the Munich-based biotech company, is breaking new ground in its financing strategy by issuing its first corporate bond to raise up to €50 million. The four-year unsecured bond, scheduled
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon AG: Subscription period for 2025/2029 corporate bond has started
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-News: Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
EQS-Adhoc: Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth
EQS-News: Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
EQS-News: Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
EQS-News: Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
EQS-News: Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
EQS-News: Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
EQS-News: Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
EQS-News: Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
EQS-News: FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
EQS-News: FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201